Dose-dense chemotherapy, characterized by standard-dose agents administered at shortened intervals with G-CSF support, has been shown to improve the disease control in patients with high-risk early breast cancer [2,4,6,8]. This evidence concerns the gene CSF3 and breast carcinoma.